1. Home
  2. SCNI vs XXII Comparison

SCNI vs XXII Comparison

Compare SCNI & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SCNI

Scinai Immunotherapeutics Ltd.

N/A

Current Price

$0.73

Market Cap

2.5M

Sector

Health Care

ML Signal

N/A

Logo 22nd Century Group Inc.

XXII

22nd Century Group Inc.

N/A

Current Price

$3.70

Market Cap

3.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCNI
XXII
Founded
2003
1998
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
3.3M
IPO Year
2014
2011

Fundamental Metrics

Financial Performance
Metric
SCNI
XXII
Price
$0.73
$3.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
46.7K
34.4K
Earning Date
01-01-0001
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
50.00
N/A
EPS
N/A
N/A
Revenue
N/A
$25,832,530.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$79.56
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.67
52 Week High
$6.18
$11.37

Technical Indicators

Market Signals
Indicator
SCNI
XXII
Relative Strength Index (RSI) 40.38 40.98
Support Level $0.65 $3.61
Resistance Level $0.94 $6.86
Average True Range (ATR) 0.09 0.39
MACD -0.01 -0.20
Stochastic Oscillator 12.73 5.99

Price Performance

Historical Comparison
SCNI
XXII

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

About XXII 22nd Century Group Inc.

22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.

Share on Social Networks: